Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the companies behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.
More and more top-performing CAPS members have been turning to the bullish side of Allos Therapeutics (Nasdaq: ALTH ) over the past year -- enough, in fact, to take it all the way from a lowly two-star rank to the highest possible five stars. A total of 245 members have given their opinion on the drug developer, with many of them offering analysis and commentary explaining the recent optimism.
The biopharmaceutical company recently received FDA approval for its relapsed or refractory peripheral T-cell lymphoma (PTCL) treatment, Folotyn, and many CAPS members are bullish on its future revenue potential. Relapsed or refractory PTCL is an aggressive type of non-Hodgkin's lymphoma, similar to diffuse large B-cell lymphoma, which Microsoft (Nasdaq: MSFT ) co-founder Paul Allen was recently diagnosed with, but occurs less frequently.
Companies like Spectrum Pharmaceutical (Nasdaq: SPPI ) , Biogen Idec (Nasdaq: BIIB ) and Roche, and Cephalon (Nasdaq: CEPH ) currently have approved treatments for non-Hodgkin's lymphoma, while others like Cell Therapeutics (Nasdaq: CTIC ) are seeking approval. But Folotyn is the first and only drug approved by the FDA to treat relapsed or refractory PTCL.
Allos Therapeutics is moving to make Folotyn available for sale in the U.S. and is boosting its sales staff with plans for a full-scale launch early next year. It raised $93 million in an equity offering to help fund its marketing efforts, and it is also looking at possible expanded indications for the drug, which investors see as a big positive. Many CAPS members agree with Jim Cramer on the bullish outlook for Allos.
Do you think Allos Therapeutics deserves its five-star status? Add your thoughts in the comments box below, or head over to CAPS to rate the company and check out all the information the community offers, absolutely free.
RSS Headlines
Fool UK